248604-63-9

Upstream product

• 130625-68-2 (2S,4S)-4-Formyloxy-pyrrolidine-1,2-dicarboxylic acid 2-(4-methoxy-benzyl) ester 1-(4-nitro-benzyl) ester 
• 96035-12-0 (2S,4S)-4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 2-(4-methoxy-benzyl) ester 1-(4-nitro-benzyl) ester 
• 248604-44-6 (2S,4R)-4-Acetylsulfanyl-pyrrolidine-1,2-dicarboxylic acid 2-(4-methoxy-benzyl) ester 1-(4-nitro-benzyl) ester 

Downstream Products

• 248604-65-1 (2S,4R)-2-((3R,4R)-3,4-Dihydroxy-pyrrolidine-1-carbonyl)-4-mercapto-pyrrolidine-1-carboxylic acid 4-nitro-benzyl ester 
• 248604-57-1 (4R,5S,6S)-3-[(3R,5S)-5-((3R,4R)-3,4-Dihydroxy-pyrrolidine-1-carbonyl)-1-(4-nitro-benzyloxycarbonyl)-pyrrolidin-3-ylsulfanyl]-6-((R)-1-hydroxy-ethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid 4-nitro-benzyl ester 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel 1β-methylcarbapenems having a new moiety at C-2

The synthesis and biological activity of the novel series of 1β- methylcarbapenems 1a-f, bearing a variety of 3'',4''-disubstituted pyrrolidinamides as substituents at C-2, are described. Of these carbapenems, diol 1a showed the most potent and well balanced antibacterial activity against Gram-positive and Gram-negative, 1a was also evaluated for pharmacokinetics and in vivo therapeutic efficacy in systemic infections.